Impax Asset Management Group plc Sells 68,709 Shares of Repligen Co. (NASDAQ:RGEN)

Impax Asset Management Group plc lowered its stake in Repligen Co. (NASDAQ:RGEN) by 6.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,058,169 shares of the biotechnology company’s stock after selling 68,709 shares during the quarter. Impax Asset Management Group plc owned 1.89% of Repligen worth $156,441,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Toronto Dominion Bank raised its holdings in Repligen by 1.5% during the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale raised its stake in shares of Repligen by 1.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock valued at $982,000 after acquiring an additional 89 shares during the last quarter. Ballentine Partners LLC boosted its holdings in shares of Repligen by 6.2% during the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 105 shares during the period. Diversified Trust Co grew its stake in shares of Repligen by 3.7% in the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock worth $372,000 after purchasing an additional 106 shares during the last quarter. Finally, CWM LLC increased its holdings in Repligen by 36.3% during the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 114 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $139.53 on Tuesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a 50 day moving average of $141.90 and a 200 day moving average of $145.60.

Insider Buying and Selling at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on RGEN shares. Stephens reiterated an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research report on Tuesday, July 30th. Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Benchmark reaffirmed a “hold” rating on shares of Repligen in a research report on Monday, August 5th. JPMorgan Chase & Co. raised their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Finally, UBS Group cut their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.